**Pharmaceutical products:** approx. 70%
**Health products:** approx. 20%
**Research and development services:** approx. 10%

**TOP 3 markets:**

1. **China:** approx. 65%
2. **Southeast Asia:** approx. 20%
3. **Europe:** approx. 10%

Zhejiang Jingxin Pharmaceutical Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, accounting for approximately 70% of total revenue. Another significant portion comes from the health products sector, while research and development services make up a smaller part of the revenue.

The company's most important market is China, which represents about 65% of the revenue. Southeast Asia and Europe are also significant markets, accounting for approximately 30% of the revenue together. This distribution demonstrates the company's strong regional presence in Asia while simultaneously building a growing presence in Europe.

**Production Sites:** Mainly in China

Zhejiang Jingxin Pharmaceutical Co., Ltd. mainly produces its products in China. The company has several production facilities located in different provinces of China to ensure efficient manufacturing and distribution. These sites are strategically chosen to serve both domestic demand and support exports.

Zhejiang Jingxin Pharmaceutical is known for its comprehensive production capacities covering a variety of pharmaceutical products, including generics and innovative medications. The company continuously invests in the modernization and expansion of its production facilities to meet international standards and enhance its competitiveness in the global market.

**Revenue Growth:** Estimated at 10-12% annually (2026, based on industry trends)
**Focus on Research and Development:** Increase in R&D budget by 15% (2025)

Zhejiang Jingxin Pharmaceutical Co., Ltd. pursues a growth strategy that heavily emphasizes innovation and research. The company continuously invests in the development of new drugs and therapies to expand its product range and stay at the forefront of medical research.

Another focus is on international expansion. Jingxin Pharmaceutical has strengthened its presence in foreign markets in recent years and plans to continue this trend to tap into new revenue sources.

Additionally, the company is leveraging strategic partnerships and alliances with other pharmaceutical companies and research institutions to harness synergies and accelerate the market introduction of new products. This strategy is intended to enhance competitiveness and ensure long-term growth.

**Main raw materials:** Active Pharmaceutical Ingredients (APIs), excipients
**Countries of origin:** India, China, Germany

Zhejiang Jingxin Pharmaceutical Co., Ltd. mainly imports Active Pharmaceutical Ingredients (APIs) and excipients needed for the production of their pharmaceutical products. India is one of the largest suppliers of APIs worldwide, which is why many Chinese pharmaceutical companies, including Zhejiang Jingxin Pharmaceutical, source raw materials from there.

Additionally, the company also imports from Germany, known for its high-quality pharmaceutical excipients. Within China itself, many raw materials are also sourced as the country has a strong pharmaceutical production base. This diversification of sources helps the company ensure supply security and optimize costs.

**Market Share in China:** 5% (estimated, 2026)
**R&D Expenses:** 8% of revenue (2025)
**Export Share:** 20% of total revenue (2025)

Zhejiang Jingxin Pharmaceutical Co., Ltd. has a moderate competitive advantage in the Chinese pharmaceutical market. The company benefits from a solid market position with an estimated 5% market share in China. This enables it to capitalize on the growing demand for pharmaceutical products domestically.

The investments in research and development, accounting for approximately 8% of revenue, underscore the company's commitment to innovation and product development. These investments are crucial to introducing new and improved products to the market in the competitive pharmaceutical sector.

Furthermore, an export share of 20% of total revenue contributes to diversifying sources of income and mitigating the risk associated with dependence on the domestic market. This strengthens the international presence and allows the company to benefit from global growth opportunities.

**Institutional Investor Share:** Estimated at 25-30% (2026)

**Insider Buys/Sells:** No significant transactions in the last year (2025)

The institutional investor share in Zhejiang Jingxin Pharmaceutical Co., Ltd. is estimated to be between 25 and 30 percent. This estimate is based on typical industry comparisons and company size.

In 2025, there were no significant insider transactions, indicating that management's confidence in the company's strategy has remained stable. This can also be seen as a positive signal for market stability and confidence in the company's future development.

**Market share of Zhejiang Jingxin Pharmaceutical Co., Ltd.:** Estimated 3-5% (2026)

**Top competitors and their market shares:**
1. **Sinopharm Group Co., Ltd.:** 10-12%
2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 8-10%
3. **China Resources Pharmaceutical Group Ltd.:** 7-9%
4. **CSPC Pharmaceutical Group Ltd.:** 6-8%
5. **Jiangsu Hengrui Medicine Co., Ltd.:** 5-7%

**Moat Analysis:**

Zhejiang Jingxin Pharmaceutical Co., Ltd. has a moderate moat, mainly characterized by its specialization in certain generics and its strong R&D department. The company benefits from a solid network in China and a growing international presence.

In comparison, companies like Sinopharm and Shanghai Pharmaceuticals have a stronger moat due to their extensive distribution networks, larger product portfolios, and stronger brand presence. These companies also benefit from strategic partnerships and a stronger financial foundation, enabling them to invest in new technologies and markets.

While Zhejiang Jingxin Pharmaceutical is competitive in its niche, it may be challenging in the coming years to compete against larger competitors with more extensive resources and broader market strategies. However, a focus on innovation and strategic alliances could help strengthen the moat.

**Revenue Growth:** 8.5% (2025)
**Research and Development Expenses:** 12% of revenue (2025)
**Market Share in China:** 5% (2025)

Zhejiang Jingxin Pharmaceutical Co., Ltd. recorded a revenue growth of 8.5% in 2025, indicating solid demand for its pharmaceutical products. The company is heavily investing in research and development, with 12% of revenue allocated to this area. This suggests a strategic focus on securing long-term growth through innovation and new products.

The 5% market share in China indicates that the company holds a significant position in the domestic market. This market position, combined with investments in research and development, could place the company in an advantageous position in the coming years to benefit from the growing demand in the healthcare sector.

Overall, Zhejiang Jingxin Pharmaceutical Co., Ltd. could be an attractive investment for investors focusing on long-term growth and innovation. However, potential investors should also consider the general market conditions and regulatory challenges in the pharmaceutical sector.

**Dividend yield:** 2.5% (2025)
**Dividend continuity:** 5 years in a row

Zhejiang Jingxin Pharmaceutical Co., Ltd. has distributed dividends in recent years, with the dividend yield standing at around 2.5% in 2025. The company has consistently paid dividends over the past five years, indicating a certain reliability in its distribution.

The continuity of dividend payments suggests that the company has a stable financial foundation that allows it to regularly distribute profits to shareholders. However, potential investors should also consider the overall profitability and future business prospects of the company to better assess the sustainability of dividend payments.